Table 4.

Studies on drug screening using lung cancer patient-derived organoids (PDOs).

Topic of Study	Drug/Targets	Outcome	Reference
Establishment of PDO biobank from 10 NSCLC patients for drug screening	Natural compounds (chelerythrine chloride, cantharidin, harmine, berberine, betaine)	Identified anticancer activity of natural compounds (chelerythine chloride, cantharidin, harmin) on both PDOs and cell lines.	[127]
Validation of NSCLC PDOs for predicting treatment response	26 anti-cancer drugs	PDOs retained the histological and genetic characteristics of the primary tumors. The in vitro response to drug screening with PDOs highly correlated with the mutation profiles in the primary tumor.	[141]
Evaluation of anticancer agents using PDOs with squamous and adenosquamous lung cancers	78 anticancer agents including molecular target drugs, immune-checkpoint inhibitors	In vitro assay systems using PDOs were suitable for evaluating molecular targeted drugs.	[142]
Establishment of biobank of 80 LCOs for drug screening	Targeted therapies including erlotinib, crizotinib, olaparib	Drug responses in LCOs correlated with genomic alterations	[19]
Establishment of 12 PDOs from lung adenocarcinoma	24 anti-cancer drugs	The drugs with the same targets displayed reproducible sensitivity patterns among organoid lines	[143]